×
About 102,075 results

Is treating severe He FH so easy? A combined treatment between lipoprotein apheresis an...
https://doi.org/10.1016/j.transci.2021.103258
Transfusion and Apheresis Science : Official Journal of T... Dal Pino B, Sbrana F et. al.

Oct 23rd, 2021 - Despite advance in pharmacotherapy of lipid disorders, many heterozygous Familial Hypercholesterolemia patients do not achieve a desirable lipid target to significantly reduce the risk of atherosclerotic cardiovascular disease. The aim of the present work is to evaluate the interaction between Lipoprotein apheresis (LA) and PCSK9i in a small FH cohort in which the guidelines therapeutic target ...

Bing-Neel Syndrome: Update on the Diagnosis and Treatment.
https://doi.org/10.1016/j.clml.2021.09.014
Clinical Lymphoma, Myeloma & Leukemia; Nanah A, Al Hadidi S

Oct 23rd, 2021 - Bing-Neel syndrome (BNS) is a rare syndrome that occurs in patients with Waldenstrom macroglobulinemia and is characterized by lymphoplasmacytic infiltration into the leptomeningeal tissue and/or the central nervous system. It represents an extramedullary manifestation which may translate into various neurological symptoms. Accurate diagnosis of BNS can be established via histologic sampling an...

Immune Checkpoint Inhibitors for Advanced Cutaneous Squamous Cell Carcinoma: A Systemat...
https://doi.org/10.1007/s11523-021-00844-z 10.1016/j.jaad.2012.11.037 10.1111/j.1365-2133.2012.10830.x 10.1016/j.jaad.2017.08.059 10.1136/bmj.f6153 10.1016/0190-9622(92)70144-5 10.1016/S0360-3016(01)01656-X 10.1016/j.jaad.2017.07.048 10.1200/JCO.2010.34.1735 10.1002/cncr.31346 10.1097/DSS.0000000000000799 10.1097/COC.0000000000000088 10.1200/JCO.2019.37.15_suppl.e21033 10.1158/1535-7163.MCT-16-0665 10.1097/EDE.0b013e3181fe7825 10.1136/bmj.315.7109.629 10.1016/S0895-4356(01)00377-8 10.1056/NEJMoa1805131 10.1200/JCO.19.03054 10.1200/JCO.19.03357 10.1016/S1470-2045(19)30728-4 10.1136/jitc-2020-000775 10.1200/JCO.2019.37.15_suppl.e21015 10.1016/j.ejca.2020.01.008 10.1007/s11864-016-0408-2 10.1016/j.ejca.2020.07.029 10.3390/cancers13143547 10.1016/j.jgo.2021.02.026 10.1111/cup.13709 10.1186/s13073-017-0424-2 10.1007/s40265-020-01302-2 10.3747/co.27.6015 10.1200/JCO.2020.38.15_suppl.TPS10084 10.1200/JCO.2019.37.15_suppl.TPS9597 10.1093/annonc/mdz394.071 10.1016/j.ejca.2008.10.026 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 10.1136/jitc-2019-000146
Targeted Oncology; Mehta NK, Li AR et. al.

Oct 23rd, 2021 - Results of early trials led to FDA approval of immune checkpoint inhibitors (ICIs) for advanced and recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (CSCC). Updated data from these trials are pending and extent of survival outcomes is undetermined. The aim of this study was to assess the efficacy of ICIs in advanced CSCC, comprising locally advanced (LA), locoregionally advanced (LR...

Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
https://clinicaltrials.gov/ct2/show/NCT04566133

Oct 22nd, 2021 - Background: Among the new cases of bile tract carcinoma (BTC) that are diagnosed every year in the United States, there are approximately 6,500 cases of gallbladder carcinoma, 3,000 cases of extrahepatic cholangiocarcinoma, and 3,000 cases of intrahepatic cholangiocarcinoma. Current treatment options for patients with cholangiocarcinoma are limited and take no account of the known biological an...

Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
https://clinicaltrials.gov/ct2/show/NCT01861106

Oct 22nd, 2021 - Background: Genetic and sporadic mutations on one allele of the GATA2 gene lead to a syndrome termed MonoMAC. MonoMAC is characterized by: 1) infections with Mycobacterium avium complex (MAC) and other opportunistic infections, 2) deficiency of monocytes, B-lymphocytes, and Natural Killer (NK) cells in the peripheral blood, and 3) progression to myelodysplastic syndrome (MDS), chronic myelomono...

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab an...
https://clinicaltrials.gov/ct2/show/NCT04736706

Oct 22nd, 2021 - The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plu...

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
https://clinicaltrials.gov/ct2/show/NCT04092270

Oct 22nd, 2021 - PRIMARY OBJECTIVE: I. To determine the safety and tolerability of peposertib (M3814) in combination with pegylated liposomal doxorubicin hydrochloride (PLD) and determine the recommended phase 2 dose (RP2D) of the combination in women with recurrent ovarian cancer. SECONDARY OBJECTIVES: I. To observe and record anti-tumor activity. II. To evaluate the pharmacokinetics of M3814 when given in com...

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo
https://clinicaltrials.gov/ct2/show/NCT04927975

Oct 22nd, 2021 - Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to evaluate how safe and effective upadacitinib is in participants with non-segmental vitiligo. Adverse effects and change in disease activity will be assessed. Upadacitinib is being evaluated for the treatment of non-segmental vitiligo. The study wi...

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
https://clinicaltrials.gov/ct2/show/NCT05027945

Oct 22nd, 2021 - Background: In 2019, investigators at the National Institutes of Health defined a new disease syndrome named VEXAS: Vacuoles in bone marrow cells, E1 enzyme mutations, X-linked, Autoinflammatory, Somatic syndrome. This syndrome is characterized by inflammatory and hematologic features and is frequently accompanied by marrow dysplasia, progressive bone marrow failure, and in some cases, the deve...

Second-line Treatment of Primary Autoimmune Hemolytic Anemia
https://clinicaltrials.gov/ct2/show/NCT05057468

Oct 22nd, 2021 - Auto-immune hemolytic anemia (AIHA) is a heterogeneous syndrome in adults. This disease is associated with significant morbidity-mortality. First-line treatment with prolonged corticosteroid is well identified but there is not enough data about cyclosporine treatment in case of resistance or dependence on steroids. the cyclosporine showed efficacy in many immune cytopenic diseases in the light ...

A Study to Investigate the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder
https://clinicaltrials.gov/ct2/show/NCT05064878

Oct 22nd, 2021 - This is a 2-part multicenter trial. Part 1 is a 20-week randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study to examine the efficacy and safety of ZX008 as an adjunctive therapy (to existing concomitant treatment with antiepileptic treatments [AETs]) in children and adults with a CDD diagnosis and uncontrolled seizures. Part 1 of the study is 20 weeks in duration and w...

Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer
https://clinicaltrials.gov/ct2/show/NCT05088889

Oct 22nd, 2021 - This is a single arm, single institution study, which aims to evaluate the efficacy and safety of combination therapy with radiosurgery nivolumab and ipilimumab as a maintenance regimen following first line induction chemotherapy in patients with metastatic pancreatic cancer. Chemotherapy will be administrated for a minimum of 4 cycles. Patients who have not progressed on chemotherapy will rece...

Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care
https://clinicaltrials.gov/ct2/show/NCT05088928

Oct 22nd, 2021 - There is an increased risk of Venous and Arterial thromboembolism in COVID-19 infection. The main reason being that the novel coronavirus SARS-CoV-2 induces hyperinflammation and subsequently immunothrombolism which is wide spread in the body3. The angiotensin converting enzyme 2 (ACE2) receptor, which is utilized by the virus to infect the host, is present throughout the human body organs and ...

Metronomic chemotherapy regimens and targeted therapies in non-Hodgkin lymphoma: The be...
https://doi.org/10.1016/j.canlet.2021.10.018
Cancer Letters; Cox MC, Bocci G

Oct 22nd, 2021 - Novel drugs are rapidly moving forward the treatment-paradigm of non-Hodgkin-lymphomas (NHLs). Notwithstanding, especially in aggressive subtypes, chemotherapy remains the pillar of treatment. Indeed, the combination of highly effective Maximum-Tolerated-Dose Chemotherapy (MTD-CHEMO) + "novel drugs", has so far, fallen short from expectations, often because it caused excessive toxicity. Metrono...

Complement C3 mediates early hippocampal neurodegeneration and memory impairment in exp...
https://doi.org/10.1016/j.nbd.2021.105533
Neurobiology of Disease; Bourel J, Planche V et. al.

Oct 22nd, 2021 - Memory impairment is one of the disabling manifestations of multiple sclerosis (MS) possibly present from the early stages of the disease and for which there is no specific treatment. Hippocampal synaptic dysfunction and dendritic loss, associated with microglial activation, can underlie memory deficits, yet the molecular mechanisms driving such hippocampal neurodegeneration need to be elucidat...

Efficacy of first-line treatment options in transplant-ineligible multiple myeloma: A n...
https://doi.org/10.1016/j.critrevonc.2021.103504
Critical Reviews in Oncology/hematology; Kiss S, Gede N et. al.

Oct 22nd, 2021 - Despite major therapeutic advances, the rational choice of the most appropriate first-line regimen in newly diagnosed transplant-ineligible multiple myeloma (TIE-MM) is currently undefined. We aimed to identify the most effective first-line treatment for TIE-MM patients. A total of 37 articles, including 34 treatments and 16,681 patients, were included in this Bayesian network meta-analysis. Th...

Outcome of Patients with Locally Advanced Metastatic Medullary Thyroid Cancer and Induc...
https://doi.org/10.1007/s12325-021-01940-2 10.1089/thy.2010.0021 10.1111/j.1365-2265.2006.02659.x 10.21037/gs.2019.12.16 10.3747/co.26.5539 10.1016/j.clon.2017.02.009 10.1002/1097-0142(19940115)73:2<432::AID-CNCR2820730231>3.0.CO;2-K 10.1677/erc.0.0080135 10.1200/JCO.2011.35.5040 10.1200/JCO.2012.48.4659 10.1093/annonc/mdx479 10.1056/NEJMoa2005651 10.1093/annonc/mdz400 10.1016/j.ejso.2019.09.184 10.1001/jamaoto.2020.1340 10.1200/JCO.2009.27.4225 10.4158/ACCR-2019-0365 10.1002/hed.26527 10.1089/thy.2011.0243 10.1089/thy.2012.0194 10.1016/j.ejca.2008.10.026 10.1158/1078-0432.CCR-10-0994 10.1089/thy.2016.0621 10.1089/thy.2015.0334 10.1089/thy.2014.0361 10.1016/j.beem.2017.04.012 10.3389/fendo.2018.00224 10.1016/j.critrevonc.2017.10.014 10.1001/jamaoncol.2020.3362
Advances in Therapy; Grasic Kuhar C, Lozar T et. al.

Oct 22nd, 2021 - The aim of our retrospective study was to evaluate the outcome of patients with metastatic medullary thyroid cancer (MTC) treated with tyrosine kinase inhibitors (TKIs) and/or chemotherapy with the emphasis on analysis on the cohort treated by induction TKI because of locally advanced metastatic MTC. We analyzed the outcome of 30 patients (21 males, 9 females; median age 63.8 years) with metast...

TG-1701 Induces Strong Response Rates, Fewer AEs in Relapsed/Refractory CLL
https://www.onclive.com/view/tg-1701-induces-strong-response-rates-fewer-aes-in-relapsed-refractory-cl

Oct 21st, 2021 - TG-1701 administered as monotherapy or in combination with ublituximab (TGTX-1101) and umbralisib (Ukoniq) demonstrated promising overall response rates (ORR) and with relatively few adverse events (AEs) in patients with chronic lymphocytic leukemia (CLL), according to lead author Chan Cheah, MBBS. He added that the agent is a more specific targeting BTK inhibitor which reduces off-target toxic...

Beta-Blocker Toxicity
https://emedicine.medscape.com/article/813342-overview

Oct 21st, 2021 - Practice Essentials Beta-adrenergic antagonist (ie, beta-blocker) toxicity can produce clinical manifestations including bradycardia, hypotension, arrhythmias, hypothermia, hypoglycemia, and seizures (see the images below). The presentation may range from asymptomatic to shock. Beta-blocker toxicity. Bradycardia is evident on a rhythm strip from a 48-year-old man who presented to the emergency ...

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT02879695

Oct 21st, 2021 - PRIMARY OBJECTIVES: I. To evaluate the safety and tolerability of the blinatumomab given in combination with nivolumab alone, or in combination with both nivolumab and ipilimumab in subjects with poor-risk, relapsed or refractory CD19+ pre-B cell acute lymphoblastic leukemia (ALL) or CD19+ mixed phenotype acute leukemia (MPAL). II. To determine the maximum tolerated dose (MTD) of the combinatio...